KROS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

KR

Volume

144.78K

Next Earnings

November 4th

Loading chart

KR

KROSKeros Therapeutics, Inc. Common Stock

KROS

Pay with—

Available Balance0.00

KR

Mkt Cap

$220.1M

Volume

144.78K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?Bristol Myers is relying on its growth portfolio including Reblozyl, Opdivo, and other key drugs to drive top-line growth as legacy drug sales decline. Reblozyl sales reached nearly $1.3 billion in H1 2026, up 23% year-over-year, with potential for further growth from new indications. However, the company faces increasing competition from Geron's Rytelo and Keros Therapeutics' elritercept in the MDS and myelofibrosis treatment space.Zacks Investment Research · Oct 7, 2026

KROS Begins Dosing in Phase II Study With Rinvatercept in DMDKeros Therapeutics announced the first patient dosing in its phase II study evaluating rinvatercept for Duchenne muscular dystrophy (DMD). The study will assess safety, tolerability, and functional improvements, with initial data expected in H1 2027. The company is also advancing rinvatercept development for ALS treatment and has a licensing agreement with Takeda Pharmaceutical for its second candidate, elritercept, with potential milestone payments exceeding $1.1 billion.Zacks Investment Research · Sep 29, 2026

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?Keros Therapeutics reported a Q2 2026 loss of $1.45 per share, missing consensus estimates, with revenues falling to zero from $18.2 million year-over-year. The company has no marketed products and is focusing on pipeline development. With $257.6 million in cash, the company expects runway into H1 2028. The stock received a Zacks Rank #3 (Hold) rating with an F VGM Score.Zacks Investment Research · Sep 2, 2026

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeDelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.GlobeNewswire Inc. · May 26, 2026

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific ConferenceKeros Therapeutics presented Phase 1 clinical trial data for rinvatercept (KER-065), a ligand trap designed to inhibit myostatin and activin A for treating neuromuscular diseases. The drug demonstrated good tolerability with no serious adverse events, increased muscle mass, decreased fat mass, and increased bone mineral density. Proteomic analysis confirmed target engagement and mechanism of action. The company plans to advance rinvatercept into two Phase 2 trials for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).GlobeNewswire Inc. · Mar 9, 2026

Keros Therapeutics Announces Final Results of Tender OfferKeros Therapeutics completed its cash tender offer to repurchase up to 10,950,165 shares of common stock at $17.75 per share, totaling approximately $194.4 million. More shares were tendered than the company could purchase, resulting in a pro-rata allocation.Benzinga · Nov 20, 2025

Keros Therapeutics Announces Preliminary Results of Tender OfferKeros Therapeutics completed a cash tender offer to repurchase up to 10,950,165 shares of its common stock at $17.75 per share, totaling approximately $194.4 million. More shares were tendered than the target, so shares will be accepted on a pro rata basis.GlobeNewswire Inc. · Nov 19, 2025

TGF-β Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightOver 25 pharmaceutical companies are developing TGF-β inhibitor drugs targeting oncology and fibrosis treatments, with promising pipeline therapies showing potential for addressing significant unmet medical needs.GlobeNewswire Inc. · Sep 23, 2025

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director NomineesKeros Therapeutics announced that leading independent proxy advisory firm Glass Lewis recommended that Keros stockholders vote 'FOR' all three of the company's director nominees for the upcoming Annual Meeting. Keros stated that the board is best equipped to oversee the strategic review process and execute on the ultimate outcome.GlobeNewswire Inc. · May 27, 2025

Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsightThe blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.GlobeNewswire Inc. · May 12, 2025

to start trading

KR

KROSKeros Therapeutics, Inc. Common Stock

KROS

Pay with—

Available Balance0.00

Your PositionYou don't own any KROS yet.

Related Tickers

Earnings